Bruce Kramer believed that researchers need to rethink the way they test new drugs on ALS patients like him. He argued that the double-blind testing model doesn't work for a devastating fatal illness like ALS. In this episode of Living While Dying, we also hear from a bio-ethicist about the decision to deny some patients access to an experimental drug.